logo
  

Abbott Announces Acquisition Of Walk Vascular - Quick Facts

Abbott (ABT) has acquired Walk Vascular, a commercial-stage medical device company. Walk Vascular's peripheral thrombectomy systems will be incorporated into the company's endovascular product portfolio. Financial terms of the deal were not disclosed.

Walk Vascular's JETi Peripheral Thrombectomy System and next-generation JETi AIO Peripheral Thrombectomy System are aspiration systems for the removal of intravascular clots. The products have received 510(k) clearance from the FDA for the aspiration and breaking up of soft emboli and thrombus from the peripheral vasculature, as well as CE Mark in Europe and approvals in other countries.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT